Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Endoxana, Leukine, IMA910 · 1 trial · 1 indication
Safety assessment with special emphasis on the inclusion of the first 6 patients enrolled according to a pre-specified enrolment plan
| Name | Type | Description |
|---|---|---|
| Endoxana, Leukine, IMA910 | DRUG | a single i.v. infusion of 300 mg/m2 Endoxana (Cyclophosphamide) and then 3 days later (visit 1) patients will start vaccination therapy with intradermal (i.d.) injections of 75µg GM-CSF followed by i.d. injections of 5.78 mg IMA90 |
| Endoxana, Leukine, IMA910, Aldara | DRUG | a single i.v. infusion of 300 mg/m2 Endoxana (Cyclophosphamide) and then 3 days later (visit 1) patients will start vaccination therapy with intradermal (i.d.) injections of 75µg GM-CSF followed by i.d. injections of 5.78 mg IMA90 followed by Aldara (Imiquimod) |
Inclusion criteria: * Aged at least 18 years * HLA type: HLA-A\*02-positive * Histologically confirmed colorectal adenocarcinoma (CRC) * Radiological evidence (CT/MRI) of unresectable locally advanced and/or metastatic CRC prior to 12 week first-line oxaliplatin-based standard chemotherapy * 12 wee...
Endoxana is a small molecule oncology drug being studied for use in renal cell carcinoma and colorectal carcinoma. It is currently in Phase 2 clinical development as an investigational therapy. The drug is being developed by Immatics N.V., a biopharmaceutical company focused on cancer treatments.
Endoxana is a small molecule therapeutic being investigated for the treatment of renal cell carcinoma and colorectal carcinoma. The specific molecular target of Endoxana has not been disclosed in available clinical trial information. It is currently in Phase 2 development for these oncology indications.
Endoxana is being developed by Immatics N.V., a biopharmaceutical company listed on the stock exchange under the ticker symbol IMTX. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with renal cell carcinoma and colorectal carcinoma.
Endoxana is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of renal cell carcinoma and colorectal carcinoma, with clinical trials ongoing to assess its potential as a cancer therapy.
Endoxana has been studied in clinical trials including NCT00523159, a Phase 2 trial in advanced renal cell carcinoma with 68 participants, and NCT00785122, a Phase 1 trial in colorectal carcinoma with 92 participants. Both trials have been completed. The trials were conducted across multiple European countries.
Endoxana is also known as IMA901 and Leukine. These names refer to the same drug product being developed by Immatics N.V. The drug has been evaluated under different names in clinical trials for renal cell carcinoma and colorectal carcinoma indications.